| __timestamp | BioMarin Pharmaceutical Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 22732000 |
| Thursday, January 1, 2015 | 152008000 | 29245000 |
| Friday, January 1, 2016 | 209620000 | 33206000 |
| Sunday, January 1, 2017 | 241786000 | 31152000 |
| Monday, January 1, 2018 | 315264000 | 10136000 |
| Tuesday, January 1, 2019 | 359466000 | 45546000 |
| Wednesday, January 1, 2020 | 524272000 | 43367000 |
| Friday, January 1, 2021 | 470515000 | 81413000 |
| Saturday, January 1, 2022 | 483669000 | 139304000 |
| Sunday, January 1, 2023 | 577065000 | 192361000 |
| Monday, January 1, 2024 | 580235000 | 159417000 |
Unlocking the unknown
In the competitive landscape of biotechnology, understanding cost dynamics is crucial. From 2014 to 2023, BioMarin Pharmaceutical Inc. and Halozyme Therapeutics, Inc. have shown distinct trends in their cost of revenue. BioMarin's costs have surged by approximately 345%, peaking in 2023, reflecting their aggressive expansion and increased production capabilities. In contrast, Halozyme's costs have grown by about 747% over the same period, indicating a significant scaling of operations. Notably, BioMarin's cost of revenue consistently outpaced Halozyme's, highlighting their larger operational scale. However, Halozyme's rapid growth in recent years suggests a strategic pivot towards increased market presence. This data provides a window into the strategic financial maneuvers of these biotech giants, offering investors and analysts a deeper understanding of their operational efficiencies and market strategies.
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs BioMarin Pharmaceutical Inc.
Cost of Revenue Comparison: Biogen Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: BeiGene, Ltd. vs BioMarin Pharmaceutical Inc.
Cost Insights: Breaking Down Viatris Inc. and Halozyme Therapeutics, Inc.'s Expenses
Who Generates Higher Gross Profit? BioMarin Pharmaceutical Inc. or Halozyme Therapeutics, Inc.
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs ADMA Biologics, Inc.
Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs PTC Therapeutics, Inc.
BioMarin Pharmaceutical Inc. vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: BioMarin Pharmaceutical Inc. vs Wave Life Sciences Ltd.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Galapagos NV
BioMarin Pharmaceutical Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Amneal Pharmaceuticals, Inc.'s Expenses